Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 372 (9645) , 1240-1250
- https://doi.org/10.1016/s0140-6736(08)61206-4
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Novo Nordisk
This publication has 33 references indexed in Scilit:
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 DiabetesDiabetes Care, 2007
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesPublished by Elsevier ,2006
- Immunogenicity of xenopeptide hormone therapiesPeptides, 2006
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.Journal of Clinical Investigation, 1998
- Secondary failure of oral hypoglycaemic agents: Frequency, possible causes, and managementDiabetes/Metabolism Research and Reviews, 1994